TeraRecon Cardiovascular.Calcification.CT vs ElucidVivo A.3
AI Verdict
Choose TeraRecon Cardiovascular.Calcification.CT if…
Choose TeraRecon Cardiovascular.Calcification.CT if your primary need is automated, rapid calcium scoring and a comprehensive assessment of coronary artery calcification burden. This tool is ideal for efficiently generating Agatston scores and other calcification measurements as part of a broader cardiac CT analysis, including vessel segmentation and functional assessment.
View TeraRecon Cardiovascular.Calcification.CT →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require detailed, quantitative analysis of arterial plaque composition and stability to stratify atherosclerosis patients and optimize treatment strategies. This tool excels at identifying and quantifying specific plaque components like Lipid-Rich Necrotic Core (LRNC) and deriving FFRct, providing critical insights beyond simple calcification for advanced risk assessment.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | TeraRecon Cardiovascular.Calcification.CT | ElucidVivo A.3 |
|---|---|---|
| Deployment | Cloud-enabled imaging platform. | Cloud and on-premise secure deployment. |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TeraRecon Cardiovascular.Calcification.CTTeraRecon emphasizes a physician-centric design with features like 'zero-click centerline creation' and 'semi-automating complex image post-processing' to enhance workflow efficiency and reduce burnout. Customers specifically highlight its 'ease of use' and intuitive interface. While ElucidVivo A.3 offers detailed visualizations, it lacks the explicit mentions of automation and user-centric workflow streamlining found for Tool A.
Clinical Value
ElucidVivo A.3ElucidVivo A.3 provides a more profound and predictive clinical insight by offering quantitative analysis of arterial plaque composition and stability, including Lipid-Rich Necrotic Core (LRNC) and deriving fractional flow reserve (FFRct). Its validation against ground-truth histology is a significant differentiator, enabling a deeper understanding of atherosclerosis beyond simple calcification scoring. TeraRecon focuses primarily on calcification detection and scoring, which is a foundational but less granular assessment.
Pricing & Value
TeraRecon Cardiovascular.Calcification.CTTeraRecon offers a transparent 'subscription-based' model with a 'single annual fee' that aims to provide operational budget flexibility and eliminate annual service renewals. In contrast, ElucidVivo A.3's pricing information is only available upon contact, making it less transparent and harder for potential customers to assess its value proposition upfront.
Enterprise Readiness
TeraRecon Cardiovascular.Calcification.CTTeraRecon explicitly states it is HIPAA compliant and has a BAA available, and its deployment as a 'Containerized application (SaMD)' or SaaS within the 'Eureka Clinical AI platform' offers flexibility and scalability. The Eureka platform is also vendor-agnostic, designed for seamless integration of various AI algorithms into enterprise imaging systems, and includes analytics for performance monitoring. ElucidVivo A.3's BAA and HIPAA compliance are not explicitly stated, and its deployment details are less comprehensive.
Innovation
ElucidVivo A.3ElucidVivo A.3 demonstrates greater innovation by providing unique, histology-validated quantitative analysis of arterial plaque composition and stability, including LRNC quantification and FFRct derivation. This moves beyond traditional diagnostic assistance to offer predictive insights for personalized atherosclerosis management. Furthermore, its ability to estimate RNA expression from CT angiography ('Virtual Transcriptomics') highlights a cutting-edge approach to precision medicine.
Support & Docs
TeraRecon Cardiovascular.Calcification.CTTeraRecon provides clearly documented customer support channels, including technical support, premier success services, and training, with contact information for phone (including a 24-hour emergency line) and email, along with readily available online user manuals. ElucidVivo A.3's available information does not explicitly detail its support offerings or documentation resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | TeraRecon Cardiovascular.Calcification.CT | ElucidVivo A.3 |
|---|---|---|
| Description | AI-powered software as a medical device (SaMD) that analyzes CT images to automatically detect and measure calcifications in the coronary arteries, providing a mask for calcium scoring systems. | FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology. |
| Company | Terarecon | Elucid Bioimaging |
| Key Features | Automatic 3D segmentation of calcified plaques in coronary arteries; Outputs mask for calcium scoring systems; Supports Agatston score, volume, mean mass (mg) measurements; Part of CT Cardiac package with zero-click centerline creation; Vessel segmentation and analysis (plaque, stenosis, curvature, tortuosity); Cardiac structure segmentation and functional analysis; Atrium & pulmonary vein analysis for EP planning; Pre-operative evaluation of coronary arteries. | AI-powered quantitative analysis of arterial plaque; Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections; Aids in stratifying patients with atherosclerosis; Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity; Validated on ground-truth histology. |
Videos
Demos, reviews, and walkthroughs featuring TeraRecon Cardiovascular.Calcification.CT and ElucidVivo A.3.